BioNTech (BNTX) stock is back in focus after the company reported encouraging new clinical data from its late stage oncology pipeline, spotlighting pumitamig and gotistobart at the 2026 ASCO meeting.

Despite the positive ASCO headlines, BioNTech’s share price return has been mixed, with a 7 day share price return of 5.08%, but a 30 day share price return down 12.53%, and a 1 year total shareholder return down 6.39%. This suggests sentiment is still stabilising.

If you are looking beyond a single oncology stock, this is a useful moment to scan the broader opportunity set in healthcare AI and see what stands out through the 34 healthcare AI stocks

With BioNTech shares down over the past year and trading below the average analyst price target, is the market overlooking the late stage oncology pipeline or is it already factoring in much of the future growth potential?

Most Popular Narrative: 81.5% Undervalued

The most followed narrative values BioNTech at $499.94 per share versus a last close of $92.25, putting a big spotlight on its oncology pipeline.

"Amputation, intoxication and radiation". If students read about our current cancer treatment in 2050, they would probably date it back to 1960-70. Certainly not dating back to the time of AI, fusion reactors or recurring missiles.

Sahin with his strength of pattern recognition and complexity reduction would certainly have started with an IT company, like many others. It is a stroke of luck that he has decided to fight against the Geissesl of humanity, because it is clear that medicine with AI, robotics and the breakdown of human metabolism into algorithms is facing a fundamental change.

Curious what kind of revenue mix, margins and future profit multiple could justify a fair value more than five times the current share price? The narrative leans heavily on oncology, AI driven drug design and a premium valuation multiple more often associated with fast growing tech leaders.

Result: Fair Value of $499.94 (UNDERVALUED)

However, this depends on late-stage trial success and regulatory approvals. Any weaker than expected uptake or pricing pressure could quickly undermine such an optimistic case.

Another View on Valuation

The popular narrative prices BioNTech at $499.94, but the current P/S ratio of 7.1x tells a cooler story. It sits below the US Biotechs average of 10.7x, yet above an estimated fair ratio of 5.3x. This combination hints at meaningful valuation risk if sentiment weakens.

For investors, the question is simple: does the oncology and infectious disease pipeline justify paying more than this fair ratio suggests, or is the stock already asking a lot for assets that are still working through trials?

Next Steps

Looking for more investment ideas?

If you stop at a single stock, you risk missing other opportunities that could better match your goals, risk tolerance and income needs.

• Spot potential bargains early by scanning screener containing 22 high quality undiscovered gems that combine solid fundamentals with lower market attention.
• Prioritise resilience by reviewing 65 resilient stocks with low risk scores that score well on financial strength and business stability.
• Strengthen the core of your portfolio using the solid balance sheet and fundamentals stocks screener (46 results) to focus on companies with robust balance sheets and consistent fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.